OBJECTIVE： To systematically review the efficacy and safety of nedaplatin or cisplatin combined with paclitaxel in the treatment of advanced non-small cell lung cancer （NSCLC） and esophageal cancer. METHOD： Retrieved from PubMed， CJFD and Wanfang Database， randomized controlled trials （RCT） about nedaplatin combined with paclitaxel （TN） or cisplatin combined with paclitaxel （TP） in the treatment of advanced NSCLC and esophageal cancer were collected. Meta-analysis was performed by using Rev Man 5.3 software after data extract and quality evaluation. RESULTS： Totally 7 RCTs were included， involving 505 patients. Results of Meta-analysis showed， there were no significant differences in the short-term efficacy [NSCLC：OR＝1.08，95％ CI（0.66，1.75），P＝0.76； esophageal cancer： OR＝1.44， 95％CI（0.68，3.06），P＝0.34]， 1-year survival rate [NSCLC：OR＝1.21， 95％CI（0.60，2.44），P＝0.59]， 2-year survival rate [NSCLC：OR＝1.01，95％CI（0.38，2.68），P＝0.99]， the incidence of Ⅲ/Ⅳ leukopenia [esophageal cancer：OR＝1.36，95％CI（0.62，2.96），P＝0.44]， incidence of Ⅲ/Ⅳ thrombocytopenia [NSCLC：OR＝1.37， 95％CI（0.64，2.92），P＝0.42； esophageal cancer：OR=0.97，95％CI（0.30，3.18），P＝0.96] and incidence of Ⅲ/Ⅳ neutropenia [NSCLC： OR＝1.38，95％CI（0.70，2.74），P＝0.35]. Compared with TP， TN can significantly reduce the incidences of nausea and vomiting [NSCLC： OR＝0.34，95％CI（0.20，0.60），P＜0.001； esophageal cancer： OR＝0.16， 95％CI（0.07，0.35），P＜0.001] and nephrotoxicity [esophageal cancer： OR＝0.10，95％CI（0.02，0.55），P＝0.009]. CONCLUSIONS： Both TN and TP show good efficacy in the treatment of NSCLC， but TN has lower incidences of astrointestinal reactions and nephrotoxicity.